SCOPUS 정보 검색 플랫폼

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 595-600

Improvement in Indices of Health Status in Outpatients with Schizophrenia Switched to Ziprasidone

(4) Weiden, Peter J a Daniel, David G b Simpson, George c Romano, Steven J d

a SUNY Downstate Medical Center (United States)

b Bioniche Development Inc (United States)

c UNIVERSITY OF SOUTHERN CALIFORNIA (United States)

d PFIZER INC (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ANXIETY; ARTICLE; ASTHENIA; BODY HEIGHT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENERAL CONDITION IMPROVEMENT; HEADACHE; HEALTH STATUS; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VERTIGO; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BODY WEIGHT; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; WITHHOLDING TREATMENT;

EID: 0345107248 PISSN: 02710749 EISSN: None Source Type: Journal
DOI: 10.1097/01.jcp.0000095347.32154.08 Document Type: Article

Times cited : (120)

References (10)

1
- 0033136622
- Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
- Daniel DG, Zimbroff DL, Potkin SG, et al, for the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20:491-505.
- (1999) Neuropsychopharmacology , vol.20 , pp. 491-505
- Daniel, D.G.¹ Zimbroff, D.L.² Potkin, S.G.³

2
- 7844224760
- Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
- Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140:173-184.
- (1998) Psychopharmacology (Berl) , vol.140 , pp. 173-184
- Keck Jr., P.¹ Buffenstein, A.² Ferguson, J.³

3
- 0031927910
- An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder
- Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
- (1998) J Clin Psychopharmacol , vol.18 , pp. 296-304
- Goff, D.C.¹ Posever, T.² Herz, L.³

4
- 0032751075
- Antipsychotic-induced weight gain: A comprehensive research synthesis
- Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156: 1686-1696.
- (1999) Am J Psychiatry , vol.156 , pp. 1686-1696
- Allison, D.B.¹ Mentore, J.L.² Heo, M.³

5
- 0004153006
- Therapeutic benefits of ziprasidone: An update of clinical trials experience
- Tandon R, Berti C. Therapeutic benefits of ziprasidone: an update of clinical trials experience. Adv Preclin Clin Psychiatry. 2000;2:1-19.
- (2000) Adv Preclin Clin Psychiatry , vol.2 , pp. 1-19
- Tandon, R.¹ Berti, C.²

6
- 0038813402
- Switching to ziprasidone from conventional antipsychotics, olanzapine, of risperidone in stable outpatients with schizophrenia
- Weiden P, Simpson G, Potkin S, et al. Switching to ziprasidone from conventional antipsychotics, olanzapine, of risperidone in stable outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580-588.
- (2003) J Clin Psychiatry , vol.64 , pp. 580-588
- Weiden, P.¹ Simpson, G.² Potkin, S.³

7
- 0034975581
- The apparent effects of ziprasidone on plasma lipids and glucose
- Kingsbury SJ, Fayek M, Trufasiu D, et al. The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry. 2001;62: 347-349.
- (2001) J Clin Psychiatry , vol.62 , pp. 347-349
- Kingsbury, S.J.¹ Fayek, M.² Trufasiu, D.³

8
- 0003327185
- Ziprasidone versus olanzapinein schizophrenia: Results of a double-blind trial
- May 5-10; New Orleans, LA
- Simpson G, Romano, SJ, Horne RL, et al. Ziprasidone versus olanzapinein schizophrenia: results of a double-blind trial. Presented at: 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, LA.
- (2001) 154th Annual Meeting of the American Psychiatric Association
- Simpson, G.¹ Romano, S.J.² Horne, R.L.³

9
- 0345408452
- Insulin resistance in olanzapine- and ziprasidone-treated patients: Results of a double-blind, controlled, 6-week trial
- May 5-10; New Orleans, LA
- Glick I, Romano SJ, Simpson G, et al. Insulin resistance in olanzapine- and ziprasidone-treated patients: results of a double-blind, controlled, 6-week trial. Presented at: 154th Annual Meeting of the American Psychiatry Association; May 5-10, 2001; New Orleans, LA.
- (2001) 154th Annual Meeting of the American Psychiatry Association
- Glick, I.¹ Romano, S.J.² Simpson, G.³

10
- 0033105824
- Neuroleptic-induced hyperprolactinemia
- Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(suppl):S75-S86.
- (1999) Schizophr Res , vol.35 , Issue.SUPPL.
- Dickson, R.A.¹ Glazer, W.M.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.